AVI adds two patents to cardiovascular program development

By Elaine Rigoli

Tampa, Fla., Aug. 3 - AVI BioPharma, Inc. said the U.S. Patent Office issued the following two patents: "Antisense Restenosis Composition and Method" and "Microbubble Compositions and Methods for Oligonucleotide Delivery."

The first patent covers the broad use of AVI-4126 to treat any vascular injury including balloon angioplasty alone or in combination with a stent. The patent also includes the use of an intravascular stent that delivers AVI-4126 either via a coating or any other method. This patent protects the AVI-Cook program through January 2020.

AVI licensed its vascular disease program to the Cook Group, Inc. in March for device delivery of the Neugene antisense drug AVI-4126, while the company is focusing internal development on coronary artery bypass graft using AVI-5126.

The second program covers the administration of a broad range of drugs, including any antisense drugs, via microbubbles to damaged vascular tissues.

The patent also covers a range of proteins and gases used to make and administer the bubbles. This patent protects this delivery method until October 2017, according to a news release.

In addition to assuming all program costs, Cook has entered into a supply agreement to purchase the drugs for development, clinical studies and commercialization from AVI, the release said.

Cook manufactures medical devices with international headquarters in Bloomington, Ind.

AVI BioPharma develops therapeutic products and is based in Portland, Ore.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.